Real‑World Study Finds Obesity Drugs Cut Hospitalizations and Healthcare Costs

A recent study published in the international journal *Diabetes, Obesity and Metabolism* examined the economic impact of sustained obesity‑treatment medication use. Researchers used the U.S. Komodo Research dataset and performed propensity‑score matching on 31,686 adults aged 55 and older who were classified as obese or overweight. The cohort was divided into a treatment group of 15,843 patients receiving the medication and a comparable control group. The analysis revealed that, even when the cost of the medication itself was excluded, patients who continued the therapy experienced fewer hospital admissions and emergency‑room visits. This reduction translated into a significant overall decrease in medical expenditures for the population studied. These findings suggest that long‑term use of obesity drugs can generate notable cost‑saving benefits for healthcare systems, beyond the direct therapeutic effects of the drugs themselves.